Mechanisms of Human Lymphoid Chromosomal Translocation
人类淋巴染色体易位的机制
基本信息
- 批准号:9756315
- 负责人:
- 金额:$ 36.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-01 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffectB-Cell LymphomasB-LymphocytesBCL2 geneBase Pair MismatchBase PairingBinding SitesBiochemicalBiochemical GeneticsBiological AssayCancer PatientCellsChemicalsChromosomal translocationCytidine DeaminaseDNADNA Double Strand BreakDNA SequenceDNA StructureDNA-Directed DNA PolymeraseDNA-Directed RNA PolymeraseDataDatabasesDependenceDirect RepeatsEnzymesEtiologyEventFrequenciesFutureGenetic TranscriptionGenomeGenomicsGoalsHumanHuman GenomeImmunoprecipitationLaboratoriesLengthLocationLymphoidLymphomaMalignant NeoplasmsMapsMethodsModelingMolecularMolecular StructureMucosa- associated lymphoid tissue lymphoma translocation protein-1MusNeoplasmsNuclearOncogenesPatientsProtein Binding DomainQuantitative GeneticsRNA Polymerase IIRepetitive SequenceReplication OriginSaccharomyces cerevisiaeSingle-Stranded DNASiteSourceStructureSumSystemTCF3 geneTestingTopoisomerase IIUntranslated RNAactivation-induced cytidine deaminaseartemisbasebisulfitebisulfite sequencingcomplement C2adesigndifferentiated B cellgenome-widehistone modificationhuman datainsightmouse modelneoplasticpermanganatepreventpromoterpublic health relevancerepairedtherapeutic evaluationtranscription factortumoryeast genetics
项目摘要
DESCRIPTION (provided by applicant): Chromosomal translocations are the key inception point of many cancers and yet the molecular mechanism of translocations in humans is unclear. We have a unique database of 1,800 neoplastic chromosomal translocations from cancer patients for which the translocation junctions have been sequenced. We exploit these data from human B-cell lymphomas to define what is distinctive about the DNA regions where these patient translocations occurred. We have identified 7 well-defined DNA fragile zones that account for the majority of human B cell lymphomas. Although the translocations can potentially span 10-100 kb regions near oncogenes, the fragile zones we have identified are only 25-600 bp in length and are 100-1000-fold more susceptible to DNA breakage than nearby DNA. Determining the molecular and structural basis of these fragile zones is the major focus of this proposal. We have determined that all of the CG and WGCW sites within these fragile zones are sites of action of AID (activation-induced deaminase) which generates G:U base-pair mismatches by converting either C to U or methyl-C to T. The resulting base-pair mismatches can then be converted to double-strand DNA breaks (DSBs). None of the 7 human fragile zones we have identified are located in or near promoters, which is where translocations occur in murine models. Importantly, AID requires single-stranded DNA (ssDNA) as a substrate. Thus, one of our major goals is to determine what causes these 25-600 bp fragile zones to achieve a ssDNA state that leads to DSBs. All of the translocations studied in this proposal occurred during human pre-B cell differentiation. We have three sources of human pre-B cells for our analyses and two of these are primary cells. Aim 1 uses four parallel approaches to define the ssDNA character of the 7 fragile zones relative to nearby DNA. In Aim 1A & B, we identify regions of ssDNA using bisulfite and permanganate chemical probing. We will determine how well the location, length and degree of ssDNA character is correlated among the 7 fragile zones and what sequences and features (DNA repeats, protein binding motifs, DNA structural motifs) are in common among the 7 fragile zones. In Aim 1C we map all noncoding RNAs in human pre-B cells to determine whether noncoding RNAs are initiated at the boundaries of the 7 fragile zones to create topological tension. In Aim 1D, we test for altered DNA structures called R-loops in the fragile zones (Yu & Lieber, 2003). For Aim 2, we had already shown that the zones are fragile when moved to other nuclear locations, even in non-lymphoid human cells. New preliminary data in Aim 2 demonstrates that these zones are fragile in an extremely sensitive and quantitative genetic assay in S. cerevisiae. We show that the bcl-2 MBR is fragile only when transcription occurs through it and in a topologically-dependent manner. Aim 2A-C tests the other 6 fragile zones for transcription- and topologically-dependent fragility, and the effect of replication origin proximity. Aim 2D-E mutagenizes the bcl-2 MBR fragile zone to determine the minimal features and its sensitivity to activated Artemis. These studies are broadly relevant to fragile zones in all cells and tumors.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL R LIEBER其他文献
MICHAEL R LIEBER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL R LIEBER', 18)}}的其他基金
Mechanisms of Human Lymphoid Chromosomal Translocation
人类淋巴染色体易位的机制
- 批准号:
10219165 - 财政年份:2016
- 资助金额:
$ 36.61万 - 项目类别:
Mechanisms of Human Lymphoid Chromosomal Translocation
人类淋巴染色体易位的机制
- 批准号:
9099617 - 财政年份:2016
- 资助金额:
$ 36.61万 - 项目类别:
Site-Specific Recombination in Human Health & Disease
人类健康中的位点特异性重组
- 批准号:
10400938 - 财政年份:2016
- 资助金额:
$ 36.61万 - 项目类别:
Site-Specific Recombination in Human Health & Disease
人类健康中的位点特异性重组
- 批准号:
10162067 - 财政年份:2016
- 资助金额:
$ 36.61万 - 项目类别:
Site-Specific Recombination in Human Health & Disease
人类健康中的位点特异性重组
- 批准号:
10618161 - 财政年份:2016
- 资助金额:
$ 36.61万 - 项目类别:
Selective Inhibitors of the Artemis Endonuclease
Artemis 核酸内切酶的选择性抑制剂
- 批准号:
8420339 - 财政年份:2012
- 资助金额:
$ 36.61万 - 项目类别:
Selective Inhibitors of the Artemis Endonuclease
Artemis 核酸内切酶的选择性抑制剂
- 批准号:
8261909 - 财政年份:2012
- 资助金额:
$ 36.61万 - 项目类别:
Mechanism and Regulation of Nonhomologous DNA End Joining
非同源DNA末端连接的机制和调控
- 批准号:
8894424 - 财政年份:2003
- 资助金额:
$ 36.61万 - 项目类别:
MECHANISM AND REGULATION OF NONHOMOLOGOUS DNA ENDJOINING
DNA非同源连接的机制和调控
- 批准号:
6596588 - 财政年份:2003
- 资助金额:
$ 36.61万 - 项目类别:
Mechanism and Regulation of Nonhomologous DNA End Joining
非同源DNA末端连接的机制和调控
- 批准号:
8111276 - 财政年份:2003
- 资助金额:
$ 36.61万 - 项目类别:
相似海外基金
Roles of immune cells derived from clonal hematopoiesis in B-cell lymphomas
克隆造血来源的免疫细胞在 B 细胞淋巴瘤中的作用
- 批准号:
24K19213 - 财政年份:2024
- 资助金额:
$ 36.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identification of novel biomarkers for EBV-associated B-cell lymphomas arising in the oral cavity
口腔中出现的 EBV 相关 B 细胞淋巴瘤的新型生物标志物的鉴定
- 批准号:
23K15982 - 财政年份:2023
- 资助金额:
$ 36.61万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Chromunities Drive Transcriptional Reprogramming in Humoral Immunity and B-cell Lymphomas
染色体驱动体液免疫和 B 细胞淋巴瘤中的转录重编程
- 批准号:
10606730 - 财政年份:2023
- 资助金额:
$ 36.61万 - 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
- 批准号:
10566833 - 财政年份:2023
- 资助金额:
$ 36.61万 - 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
- 批准号:
10987699 - 财政年份:2023
- 资助金额:
$ 36.61万 - 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
- 批准号:
10541285 - 财政年份:2022
- 资助金额:
$ 36.61万 - 项目类别:
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
- 批准号:
10540952 - 财政年份:2022
- 资助金额:
$ 36.61万 - 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
- 批准号:
10703446 - 财政年份:2022
- 资助金额:
$ 36.61万 - 项目类别:
Therapeutic potential of novel antibody-oligonucleotide conjugate for intractable B-cell lymphomas
新型抗体-寡核苷酸缀合物治疗难治性 B 细胞淋巴瘤的潜力
- 批准号:
22K08497 - 财政年份:2022
- 资助金额:
$ 36.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
- 批准号:
10707312 - 财政年份:2022
- 资助金额:
$ 36.61万 - 项目类别:














{{item.name}}会员




